Our Patient Centricity Team combines behavioral science, novel insights, research, and partnerships to bring real-world perspectives of patients into our process.
To learn more about our Patient Partnership Team, and to read about some of the projects
and initiatives we have delivered with patients, for patients, and hear what patient organization
representatives say about working with us, download our
Annual Report.
We put patients first, working to better understand their needs. Our access support, C³ Prize, and commitment to diverse clinical trials are just the beginning of our promise to change the course of cancer treatment together.
Astellas Pharma Support Solutions is designed to provide a single point of contact to help patients overcome challenges accessing Astellas products.
See the enrollment forms below to get started:
For more detailed information such as help with authorization forms, denial appeal letters, and more,
visit the Astellas Pharma Support website
Cancer is complex. Astellas Oncology recognizes the complexities of the cancer journey – in addition to medicine, people with cancer need comprehensive care.
At Astellas, we believe that having a conscious awareness of the patient in all activities, from every area of the company every single day, ensures we make the greatest impact possible on patients throughout their healthcare journey.
That’s why we are committed to fueling big ideas that tackle everyday challenges in cancer care beyond medicine. The C³ (Changing Cancer Care) Prize awards grants and resources to advance ideas that make a big impact in the cancer community. The C³ Prize directly reflects the mission of Astellas Oncology: to make every day better for those impacted by cancer.
Idea:
A mobile app to help cancer patients track their own symptom data, enabling them to
have
greater control in their treatment. The app aims to reduce clinical team burden,
drive deeper
understanding of the patient's daily data and improve outcomes.
Idea:
An app that connects cancer patients with the specialists and hospitals they need to access care.
Idea:
Expand the reach and impact of Nanny Angel Network, which delivers free, specialized childcare for mothers with cancer.
Astellas Oncology is committed to bringing underrepresented communities and demographics into more clinical trials.
A 2020 FDA review found that clinical trial participants' demographics differed significantly from the
general U.S. population -- resulting in drugs being understudied in marginalized demographics.
Percent Participation in Clinical Trial by Subpopulation* for New Molecular Entities and Therapeutic Biologics Approved in 2020
| White | Black or African American |
Hispanic | Asian |
|---|---|---|---|
| 75% | 8% | 11% | 6% |
*The percentage of all other races combined (American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, Other, Unknown/Unreported) makes up to 100% of race category.
*The percentage of Non-Hispanic and Unknown/Unreported ethnicity makes up to 100% of ethnicity category.
*The percentage of patients from anywhere else in the world makes up to 100% of geographic category.
Gov W. SNAPSHOTS SUMMARY REPORT DRUG TRIALS.; 2021.
https://www.fda.gov/media/145718/download
Population Distribution by Race/Ethnicity: 2021
| White | Black or African American |
Hispanic | Asian | American Indian/ Alaska Native |
Native Hawaiian/ Other Pacific Islander |
Multiple Races |
|---|---|---|---|---|---|---|
| 58.2% | 11.6% | 19.0% | 5.7% | 0.5% | 0.2% | 4.9% |
Population Distribution by Race/Ethnicity. KFF. Published October 23, 2020.
https://www.kff.org/other/state-indicator/distribution-by-raceethnicity/?currentTimeframe=1&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
You are now leaving www.astellasoncology.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
